DEVELOPMENT AND VALIDATION OF A HPLC/PDA METHOD FOR SIMULTANEOUS QUANTIFICATION OF AMLODIPINE BESYLATE AND VALSARTAN IN DISSOLUTION MEDIA

Huynh Thi My Duyen1,, Tran Huu Loc1, Truong Phu Vinh1, Tran Dung Tam1, Huynh Thien Hai1
1 Can Tho University of Medicine and Pharmacy

Nội dung chính của bài viết

Tóm tắt

Background: Valsartan, an angiotensin blocker, is often combined with amlodipine (a calcium channel antagonist) in the current treatment of hypertension. There is a generic brand-name drug Exforge® which has been proven to be clinically effective. However, its price is high, making it quite difficult to access, especially in low- and middle-income countries. Therefore, research and development of generic drugs is essential. In addition, research on simultaneous quantification of amlodipine and valsartan in the dissolution medium must be performed to serve as a basis for comparing in vitro equivalence between the two finished products. Objectives: Investigation of the mobile phase for separating amlodipine and valsartan using the isocratic elution method and validation of the simultaneous quantification of amlodipine and valsartan in three different dissolution media with pH of 1.2, 4.5, and 6.8. Materials and methods: Experimental methods on finished tablets containing amlodipine and valsartan. Results: A procedure for simultaneous quantification of amlodipine and valsartan has been developed and validated in three dissolution media using the HPLC method with DAD detector, ZORBAX Eclipse Plus C18 reversed-phase column (4.6 x 250 mm; 5m), isocratic elution method, detection wavelength of 237 nm, flow rate of 1 mL/min, an injection volume of 20 µL, and mobile phase composed of acetonitrile-triethylamine 0.7% (adjusted to pH 3.0 with 0.05% of phosphoric acid) with a ratio of 40:60. The quantitative method achieves linearity with a correlation coefficient R2>0.999 and the linearity for amlodipine and valsartan was determined in the range at pH of 1.2 (0.25-10 µg/mL and 2-160 µg/mL), at pH of 4.5 and 6.8 (0.5-10 µg/mL and 8-160 µg/mL). The values of amlodipine and valsartan content in the test sample on the same day and between two different days were less than 2.0%. The recovery rate ranged from 98% to 102% with the relative standard deviation (RSD) not exceeding 2.0%. Conclusions: The HPLC method with the above chromatographic conditions can be applied for simultaneous quantification of amlodipine and valsartan in three dissolution media with various pH.

Chi tiết bài viết

Tài liệu tham khảo

1. KOKILAMBIGAI, K. S., et al. Analytical and Bioanalytical Techniques for the Quantification of the Calcium Channel Blocker-Amlodipine: A Critical Review. Critical Reviews in Analytical Chemistry, 2021, 51.8: 754-786.
2. Ministry of Health. National Pharmacopoeia of Vietnam. 2018. 187-188 and 976-979.
3. Ravangard Ramin,et al,. Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran. Health Economics Review. 2023. 13(1). 1-11. DOI.org/10.1186/s13561-023-00457-4.
4. WANG, Kang-Ling, et al. Amlodipine/valsartan fixed-dose combination treatment in the management of hypertension: A double-blind, randomized trial. Journal of the Chinese Medical Association, 2020, 83.10: 900-905.
5. Ministry of Health. Circular 07/2022/tt-byt dated September 5, 2022, regulates drugs subject to bioequivalence testing and requirements for bioequivalence research data reporting documents in drug circulation registration in Vietnam issued by the Minister of Health. 2022. Hanoi.
6. Binuraj Nair K, Maya Sharma, Sandip Zine. In-vitro Study and In-vivo Predictions of Valsartan and Amlodipine Capsules through Micro Tablets. Journal of Pharmaceutical Research International. 2021. 33(46B). 335-349. DOI:10.9734/jpri/2021/v33i46B32947
7. Ministry of Health. Circular regulates drugs must undergo bioequivalence testing and requirements for bioequivalence research data reporting documents in drug circulation registration in Vietnam. 2022. Hanoi.
8. United States Pharmacopeia (44th ed.). Rockville, MD: United States Pharmacopeial Convention, Inc.. 2020. 564.
9. ICH Harmonized Tripartite Guideline. Validation of Analytical Procedures: Text and methodology, Q2(R1). 2014. 1-18.
10. ABDULLAH, Azman; RUSLI, Muhammad Fadzli. Valsartan: a brief current review. Pharmacophore, 2020, 1.11: 2.
11. Harry G. Brittain. Valsartan (Profiles of drug substances, excipients, and related methodology). Academic Press. 2020. 1st Edition, volume 45, 1-41.
12. Manish Sharma, et al. Concurrent Estimation of Amlodipine Besylate, Hydrochlorothiazide, and Valsartan by RP-HPLC, HPTLC, and UV–Spectrophotometry. Journal of Chromatographic Science. 2014. 52(1). 27-35. DOI: 10.1093/chromsci/bms200.